#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acromegaly Marginal zone lymphoma refractory Anal cancer recurrent Fibrodysplasia ossificans progressiva Kawasaki's disease Urethral valves C3 glomerulopathy B-cell small lymphocytic lymphoma recurrent Fibrosarcoma metastatic Cardiac failure acute Craniopharyngioma Dent's disease Hyperphagia Acute graft versus host disease in liver Piriformis syndrome More trials…

    Learn about Rare Diseases

    Hereditary motor and sensory neuropathy – Treatment Hyperoxaluria – Diagnostics KBG syndrome – Basic Information Hereditary neuropathic amyloidosis – Basic Information Brain stem glioma – Life with Disease Metachromatic leukodystrophy Methylmalonic acidaemia – Basic Information Pemphigoid – Basic Information Pemphigus – Life with Disease Wiskott-Aldrich syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    A3907 Odm-111 Water For Injections Reparixin Emicizumab BENZYDAMINE HYDROCHLORIDE Ep262 Formoterol Fumarate Flortaucipir (18F) Human Immunoglobulin G Thiopental Sodium Tofersen Timrepigene Emparvovec Valproate Semisodium GSKVX000000034797 Methylprednisolone Mosliciguat Nadroparin Calcium IDOR-1117-2520C GOCATAMIG More therapies…

    Learn about Your Condition

    Intestinal obstruction Dysmenorrhoea Encephalitis Japanese B Vascular malformation Enteritis Dystonic tremor Body mass index increased Cutaneous T-cell lymphoma Juvenile idiopathic arthritis Premature baby Epiphysiolysis Diabetes mellitus Ehlers-Danlos syndrome Thalassaemia Prader-Willi syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive breast cancer

  • Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer female
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Ribociclib
    Germany

  • Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Neratinib
    Croatia France Italy Spain

  • Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    • Breast cancer female
    Investigated Drugs:
    • Capivasertib
    • Fulvestrant
    Belgium France Germany Hungary Italy Poland +1

  • Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Anastrozole
    • Exemestane
    Belgium France Germany Italy Poland Portugal +1

  • Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Db-1303
    • Capecitabine
    • Paclitaxel
    Belgium France Germany Hungary Italy Poland +1

  • Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Op-1250
    • PALAZESTRANT
    • Anastrozole
    Austria Belgium Bulgaria Czechia France Germany +7
Previous Page
1 2 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!